PE20211247A1 - Sulfonas y sulfoxidos biciclicos y metodos de usos de los mismos - Google Patents
Sulfonas y sulfoxidos biciclicos y metodos de usos de los mismosInfo
- Publication number
- PE20211247A1 PE20211247A1 PE2020000353A PE2020000353A PE20211247A1 PE 20211247 A1 PE20211247 A1 PE 20211247A1 PE 2020000353 A PE2020000353 A PE 2020000353A PE 2020000353 A PE2020000353 A PE 2020000353A PE 20211247 A1 PE20211247 A1 PE 20211247A1
- Authority
- PE
- Peru
- Prior art keywords
- ring
- cycloalkyl
- compound
- sulfoxides
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
Abstract
Referido a un compuesto de formula I, o una sal farmaceuticamente aceptable del mismo, en donde R1 es alquilo C1-6, cicloalquilo C3-C6, CH2(cicloalquilo C3-C6), entre otros; n es 0, 1 o 2; el anillo A y el anillo B se fusionan para formar un sistema anular policiclico; en donde A es un anillo heteroaromatico de 5 miembros, en el que se sustituye opcionalmente C con un sustituyente tal como F, Cl, metilo o trifluorometilo; y B es un anillo carbociclico de 4 a 8 miembros, o anillo heterociclico de 4 a 8 miembros, entre otros; que tiene de 1 a 3 heteroatomos seleccionados entre N, O y S; p es 1 o 2 y q es 0 o 1; o p es 0 , y q es1; RB1 es R3a o R3b, cada R3a y R3b, cuando estan presentes son independientemente halogeno, deuterio, hidroxilo, entre otros; y RB2 es R4 y R4 es alquilo C1-C6, haloalquilo C1-C6, cilcoalquilo C3-C6, entre otros. Un compuesto seleccionado es 2-(difluorometilsulfinil)-5-fenil-6,7-dihidro-5H-pirrolo[1,2-b][1,2,4]triazol. Este compuesto son Sulfonas y sulfoxidos biciclicos que tienen actividad inhibitoria de la quinasa de la proteina 1 de interaccion con receptores (RIP1 quinasa); tambien se refiere a compuestos intermedios, metodos de preparacion de los mismos, y su uso en el tratamiento de enfermedades y trastornos asociados a inflamacion, muerte celular y otros.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762579392P | 2017-10-31 | 2017-10-31 | |
PCT/EP2018/079772 WO2019086494A1 (en) | 2017-10-31 | 2018-10-30 | Bicyclic sulfones and sulfoxides and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211247A1 true PE20211247A1 (es) | 2021-07-13 |
Family
ID=64051580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020000353A PE20211247A1 (es) | 2017-10-31 | 2018-10-30 | Sulfonas y sulfoxidos biciclicos y metodos de usos de los mismos |
Country Status (21)
Country | Link |
---|---|
US (2) | US11072617B2 (es) |
EP (1) | EP3704097B1 (es) |
JP (1) | JP2021501183A (es) |
KR (1) | KR20200083515A (es) |
CN (1) | CN111278809A (es) |
AR (1) | AR113811A1 (es) |
AU (1) | AU2018360270A1 (es) |
BR (1) | BR112020008446A2 (es) |
CA (1) | CA3078688A1 (es) |
CL (1) | CL2020001062A1 (es) |
CO (1) | CO2020003475A2 (es) |
CR (1) | CR20200168A (es) |
IL (1) | IL273847A (es) |
MA (1) | MA50503A (es) |
MX (1) | MX2020003451A (es) |
PE (1) | PE20211247A1 (es) |
PH (1) | PH12020550537A1 (es) |
RU (1) | RU2020115915A (es) |
SG (1) | SG11202002877RA (es) |
TW (1) | TW201922748A (es) |
WO (1) | WO2019086494A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11071721B2 (en) | 2016-12-02 | 2021-07-27 | Genentech, Inc. | Bicyclic amide compounds and methods of use thereof |
CA3185865A1 (en) | 2017-07-14 | 2019-01-17 | F. Hoffmann-La Roche Ag | Bicyclic ketone compounds and methods of use thereof |
TW202214617A (zh) | 2020-06-02 | 2022-04-16 | 法商賽諾菲公司 | 作為ripk1抑制劑之異㗁唑啶及其用途 |
US11897876B2 (en) | 2021-11-11 | 2024-02-13 | Genzyme Corporation | Isoxazolidines as RIPK1 inhibitors and use thereof |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1620508A1 (de) * | 1965-07-23 | 1969-09-18 | Thomae Gmbh Dr K | Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3948903A (en) | 1972-12-15 | 1976-04-06 | Parke, Davis & Company | Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
GB8610530D0 (en) * | 1986-04-30 | 1986-06-04 | Fbc Ltd | Herbicides |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
AU677216B2 (en) | 1992-07-27 | 1997-04-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Targeting of liposomes to the blood-brain barrier |
US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
WO1998056376A1 (en) | 1997-06-13 | 1998-12-17 | Sugen, Inc. | Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction |
JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
WO2002017930A2 (en) | 2000-08-30 | 2002-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
AU2002322720B2 (en) | 2001-07-25 | 2008-11-13 | Raptor Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
KR101050700B1 (ko) | 2002-08-26 | 2011-07-20 | 다케다 야쿠힌 고교 가부시키가이샤 | 칼슘 수용체 조절 화합물 및 이의 용도 |
KR101111477B1 (ko) | 2002-12-03 | 2012-02-23 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 치료제와 연결된 콜레스테롤을 포함하는 접합체 |
TW200509910A (en) | 2003-05-02 | 2005-03-16 | Elan Pharm Inc | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists |
EP1663239A4 (en) | 2003-09-10 | 2008-07-23 | Cedars Sinai Medical Center | KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER |
EP2083009A1 (de) | 2008-01-22 | 2009-07-29 | Grünenthal GmbH | Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln |
US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
ES2552514T3 (es) | 2011-11-03 | 2015-11-30 | Hoffmann-La Roche Ag | Compuestos bicíclicos de piperazina |
EP2852584B1 (en) | 2012-05-22 | 2018-02-28 | F. Hoffmann-La Roche AG | Substituted dipyridylamines and uses thereof |
BR112015016395A2 (pt) | 2013-01-18 | 2017-07-11 | Hoffmann La Roche | pirazóis 3-substituídos e uso como inibidores de dlk |
TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 (二) |
CN105164114B (zh) | 2013-05-01 | 2018-03-23 | 豪夫迈·罗氏有限公司 | C‑连接的杂环烷基取代的嘧啶类和它们的用途 |
CN110003178B (zh) | 2013-05-01 | 2022-02-25 | 豪夫迈·罗氏有限公司 | 二杂芳基化合物及其用途 |
CA2917198C (en) | 2013-07-10 | 2022-06-07 | Vertex Pharmaceuticals Incorporated | Fused piperidine amides as modulators of ion channels |
MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
JP6554481B2 (ja) | 2014-03-26 | 2019-07-31 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | オートタキシン(atx)及びリゾホスファチジン酸(lpa)産生の阻害剤としての縮合[1,4]ジアゼピン化合物 |
WO2016027253A1 (en) | 2014-08-21 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
WO2016142310A1 (en) | 2015-03-09 | 2016-09-15 | F. Hoffmann-La Roche Ag | Tricyclic dlk inhibitors and uses thereof |
NZ737297A (en) | 2015-07-02 | 2024-03-22 | Hoffmann La Roche | Bicyclic lactams and methods of use thereof |
US10709692B2 (en) | 2015-12-04 | 2020-07-14 | Denali Therapeutics Inc. | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) |
US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
EP3414239A2 (en) | 2016-02-05 | 2018-12-19 | Denali Therapeutics Inc. | Inhibitors of receptor-interacting protein kinase 1 |
US11071721B2 (en) | 2016-12-02 | 2021-07-27 | Genentech, Inc. | Bicyclic amide compounds and methods of use thereof |
US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
CA3185865A1 (en) | 2017-07-14 | 2019-01-17 | F. Hoffmann-La Roche Ag | Bicyclic ketone compounds and methods of use thereof |
KR20200070297A (ko) | 2017-10-11 | 2020-06-17 | 에프. 호프만-라 로슈 아게 | Rip1 키나아제 억제제로서 사용하기 위한 이환형 화합물 |
-
2018
- 2018-10-30 PE PE2020000353A patent/PE20211247A1/es unknown
- 2018-10-30 EP EP18796020.8A patent/EP3704097B1/en active Active
- 2018-10-30 BR BR112020008446-8A patent/BR112020008446A2/pt not_active Application Discontinuation
- 2018-10-30 RU RU2020115915A patent/RU2020115915A/ru unknown
- 2018-10-30 SG SG11202002877RA patent/SG11202002877RA/en unknown
- 2018-10-30 CN CN201880070578.0A patent/CN111278809A/zh active Pending
- 2018-10-30 AU AU2018360270A patent/AU2018360270A1/en active Pending
- 2018-10-30 AR ARP180103157A patent/AR113811A1/es unknown
- 2018-10-30 CA CA3078688A patent/CA3078688A1/en active Pending
- 2018-10-30 WO PCT/EP2018/079772 patent/WO2019086494A1/en active Application Filing
- 2018-10-30 CR CR20200168A patent/CR20200168A/es unknown
- 2018-10-30 TW TW107138469A patent/TW201922748A/zh unknown
- 2018-10-30 KR KR1020207015138A patent/KR20200083515A/ko not_active Application Discontinuation
- 2018-10-30 JP JP2020524177A patent/JP2021501183A/ja active Pending
- 2018-10-30 US US16/175,206 patent/US11072617B2/en active Active
- 2018-10-30 MA MA050503A patent/MA50503A/fr unknown
- 2018-10-30 MX MX2020003451A patent/MX2020003451A/es unknown
-
2020
- 2020-03-25 CO CONC2020/0003475A patent/CO2020003475A2/es unknown
- 2020-04-06 IL IL273847A patent/IL273847A/en unknown
- 2020-04-20 CL CL2020001062A patent/CL2020001062A1/es unknown
- 2020-04-30 PH PH12020550537A patent/PH12020550537A1/en unknown
-
2021
- 2021-06-06 US US17/340,082 patent/US20230002391A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20200083515A (ko) | 2020-07-08 |
RU2020115915A (ru) | 2021-12-01 |
US11072617B2 (en) | 2021-07-27 |
CR20200168A (es) | 2020-07-12 |
US20230002391A1 (en) | 2023-01-05 |
JP2021501183A (ja) | 2021-01-14 |
MX2020003451A (es) | 2020-08-03 |
TW201922748A (zh) | 2019-06-16 |
BR112020008446A2 (pt) | 2020-12-29 |
RU2020115915A3 (es) | 2022-05-06 |
CN111278809A (zh) | 2020-06-12 |
EP3704097B1 (en) | 2023-10-25 |
CA3078688A1 (en) | 2019-05-09 |
CL2020001062A1 (es) | 2020-08-21 |
EP3704097A1 (en) | 2020-09-09 |
US20190127382A1 (en) | 2019-05-02 |
AR113811A1 (es) | 2020-06-10 |
AU2018360270A1 (en) | 2020-03-26 |
EP3704097C0 (en) | 2023-10-25 |
MA50503A (fr) | 2020-09-09 |
CO2020003475A2 (es) | 2020-04-24 |
WO2019086494A1 (en) | 2019-05-09 |
PH12020550537A1 (en) | 2021-03-22 |
SG11202002877RA (en) | 2020-04-29 |
IL273847A (en) | 2020-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211247A1 (es) | Sulfonas y sulfoxidos biciclicos y metodos de usos de los mismos | |
PE20211246A1 (es) | Compuestos biciclicos para su uso como inhibidores de rip1 quinasa | |
DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
DOP2022000100A (es) | Agonista del receptor glp-1 y uso de este | |
CY1124800T1 (el) | Παραγωγο πυριδο[3,4-d]πυριμιδινης και φαρμακευτικως αποδεκτο αλας αυτου | |
CL2019001633A1 (es) | Imidazol pirrol piridina como inhibidores de la familia jak de quinasas. | |
DOP2016000158A (es) | Análogos de cortistatina y síntesis y usos de los mismos. | |
AR102227A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
CL2017002922A1 (es) | Agonistas de triazol del receptor apj | |
DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
CL2019001626A1 (es) | Inhibidores de pequeñas moléculas de la familia jak de quinasas. | |
AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
CL2018003060A1 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak. | |
CL2017000270A1 (es) | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias. | |
WO2015132799A3 (en) | Heterocyclic compounds | |
AR067540A1 (es) | Compuesto de aril (isoxazol-4-il-metoxilo) , su uso para preparar un medicamento y composicion farmaceutica que lo comprende | |
PE20181086A1 (es) | Acetamida tienotrizolodiazepinas y usos de las mismas | |
CL2016000495A1 (es) | Compuestos derivados de triazolo[4,5-d]pirimidina, agonistas de receptor cb2; proceso de preparación; composición que los comprende y el uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamación, diabetes mellitus, entre otras enfermedades. | |
AR107927A1 (es) | Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento | |
DOP2015000184A (es) | Derivados de triazolona de piridinilo y piridinilo fusionado | |
AR106100A1 (es) | Compuestos bicíclicos como inhibidores duales atx / ca | |
AR101261A1 (es) | Compuesto de tetrahidropirrolo[1,2:3,4]imidazo[1,2-c]pirimidin-1(6h)-ona y composición farmacéutica que lo comprende | |
PE20190339A1 (es) | 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 |